CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 37 enrolled
Drug / intervention
Pramlintide +2 moredrug
Likely dose
Pramlintide 15 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01269047
NCT01269047Phase 4Completed
CompareCT.gov

Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-prandial Hyperglycemia

Albert Einstein College of Medicine·interventional·Posted Jan 4, 2011·Updated Apr 12, 2018

In Brief

A Phase 4 clinical trial evaluating Pramlintide, Exenatide, and 1 other intervention for Type 1 Diabetes. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The main purpose of the study is to determine the effects of 16 weeks of adjunctive pramlintide or exenatide use on glycemic control in Type 1 Diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 4, 2011
Enrollment StartAug 1, 2009
Primary CompletionAug 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 15.5 years ago

Interventions

Pramlintidedrug

Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months

Exenatidedrug

Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months

Insulindrug

Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.